IRIDEX reports lower revenue: what it means for IRIX stock

Published on 10/05/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IRIDEX posted USD 12.57 million revenue in the second quarter and kept USD 51.00-53.00 million guidance. For IRIX stock, growth is 1.00-5.00 percent.

IRIX, US4626841013, Illustration mit AI erstellt.

IRIDEX Corporation (ISIN US4626841013) reported USD 12.57 million of revenue for the second quarter of 2026, down from USD 13.60 million in the prior-year period, according to the Globe and Mail on August 18, 2026. The result puts the companys glaucoma growth beside a weaker retina business, making product mix central to the stock story.

Revenue fell in the second quarter

The second-quarter revenue decline reflected lower retina product sales and international commercial transitions. Retina product revenue was USD 6.50 million, compared with USD 8.00 million a year earlier, while Cyclo G6 product-family revenue rose 19.00 percent to USD 3.90 million, according to the Globe and Mail.

The operating contrast was sharper in unit demand. Cyclo G6 probe volume reached 17,700 units in the second quarter, up from 13,100 units in the prior-year period, a 35.00 percent increase. Laser system sales declined to 18 units from 35 units because of order timing in Europe, the Middle East and Africa.

Guidance depends on glaucoma growth

Management reaffirmed full-year 2026 revenue guidance of USD 51.00 million to USD 53.00 million, excluding Middle East revenue. On a comparable basis, the range implies 1.00 percent to 5.00 percent pro forma growth over 2025, according to the Globe and Mail.

The company also expects low-double-digit glaucoma growth in the second half of 2026, while retina growth is projected in the low-single-digit range. That outlook leaves the Cyclo G6 platform as the clearest quantified support for the annual target, while relocation-related safety-stock purchases are expected to pressure cash on hand through 2026.

IRIX remains a small-cap medical device stock

IRIX last stood at USD 0.64 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, compared with a prior close of USD 0.63. The 52-week range was USD 0.61 to USD 1.65, placing the latest quote USD 1.01 below the high, while market capitalization stood at USD 11.1 million.

IRIDEX develops laser systems, delivery devices and consumable instruments for ophthalmology, including treatments for glaucoma and retinal disease. For investors, the central numerical test is whether higher Cyclo G6 probe utilization can offset the USD 1.50 million year-over-year decline in second-quarter retina revenue.